Testing effectiveness (Phase 2)Ended earlyNCT05243524
What this trial is testing
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Who this might be right for
Platinum-resistant Epithelial Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.) 16